Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi Pasteur announces publication of dengue vaccine Asian efficacy study results


Thursday, 10 Jul 2014 07:03pm EDT 

Sanofi SA:Vaccines division Sanofi Pasteur announces publication in The Lancet of detailed results of its first phase III dengue vaccine efficacy study conducted in five countries in Asia.Results show overall efficacy against symptomatic dengue of 56.5 pct in children aged 2 to 14 years old after three-dose vaccination schedule.Analyses show 88.5 pct reduction of dengue haemorrhagic fever, severe form of dengue, according to WHO criteria.Study also shows clinically important reduction in risk of hospitalization due to dengue by 67 pct during study.Results to be supplemented by results from second, large-scale phase III study in Latin America and Caribbean, including more than 20,000 children and adolescents aged 9 to 16 years old from Brazil, Colombia, Honduras, Mexico and Puerto Rico. 

Company Quote

77.27
0.34 +0.44%
24 Jul 2014